Skip to content

Intellia Therapeutics

US · NTLA #2899 by market cap Listed 2016
10.00 +0.48 +5.04%
Periodic snapshot; not a real-time feed. · 2026-11-20 20:01

Price chart

Pre-market 9.28 -2.52%
After-hours 10.00 +0.01%
Overnight 9.40 -1.26%
17.849.5210.002026-05-262026-11-20
MA5MA10MA20MA60
— MA5 — MA10 — MA20 — MA60
Reader sentiment Are you bullish or bearish on NTLA?

Anonymous reader poll. Unscientific, not investment advice.

✦ StockVane Quant Insights how this is computed

Quant Sentiment Neutral
  • Recent price momentum is +2.4% on average (3-month/1-year).
  • Main-fund capital flow has been a net outflow over the last 45 sessions.
  • Short interest has fallen to 31.7% of float.
  • Analyst tilt is Hold.
Quant Technical Outlook Bearish
  • Price is below its 20-day average and below its 60-day average.
  • The 20-day average is below the 60-day average, a short-term downtrend.
Quant Rating, last 30 days E → D

Computed by a StockVane algorithm from historical price, valuation and analyst data - not a person, not a forecast guarantee, and not investment advice.

Factor grades

Ranked against 2848 U.S. stocks StockVane covers.

Last computed: 2026-11-22 02:27 UTC

Data coverage: 4 of 6 factors. Missing data is not a zero score.

Overall C-

The radar needs all six factors. Available grades are shown below.

Valuation N/A

How expensive the stock is versus earnings, sales and its own 5-year history.

Not enough data to grade this factor.

Growth N/A

How fast revenue, profit and free cash flow are compounding.

Not enough data to grade this factor.

Profitability F

How much profit the business keeps from each dollar of sales and capital.

Operating margin -651.7% Better than 4%
Net margin -609.9% Better than 3%
Return on equity -53.5% Better than 9%
Return on invested capital -47.9% Better than 6%
Momentum C

Recent price strength, skipping the latest month to avoid short-term noise.

3-month return -22.1% Better than 28%
6-month return -20.6% Better than 26%
12-month return (ex latest month) 36.5% Better than 75%
Distance below 52-week high 45.9% Better than 23%
Financial Health A

Balance-sheet strength: leverage, liquidity and interest coverage.

Current ratio 5.1x Better than 86%
Debt to assets 11.1% Better than 68%
Analyst View B-

What the Street thinks: share of Buy ratings and upside to the average target.

Analysts rating Buy 36.4% Better than 19%
Upside to average target 92.0% Better than 82%

Grades are relative rankings, not forecasts: A+ is the top 5% of the covered stocks on a factor, F the bottom 3%. Valuation is not adjusted for sector. Background recomputation is scheduled every 6 hours; actual computation time is shown above, and source datasets have different reporting dates. Not investment advice or tailored to your financial situation.

Performance

1W +3.09%
1M -15.54%
3M -19.61%
6M -18.43%
YTD +11.23%
1Y +24.38%
3Y -66.97%
5Y -92.28%

Key statistics

Price & volume

Prev close
9.52
Open
9.34
Day range
9.30 - 10.40
Avg price
10.05
Volume
15.19M
Turnover
152.73M
Amplitude
11.50%
52-week range
8.09 - 18.48

Valuation

P/E
-2.62
P/E (TTM)
-2.99
P/B
2.29
EPS
-3.81
Net profit
-534.77M
Net assets
613.09M

Share structure

Market cap
1.40B
Float cap
1.34B
Shares out
140.36M
Float shares
134.45M

Dividend & listing

Dividend (TTM)
0.00
Listing date
2016-05-06
52-week range 18% of range
8.09 18.48

45.9% below the 52-week high

Trading activity

Net capital flow main funds, last 45 sessions

-14.36M net over the window

Short interest

Shares short
44.36M
As of
2026-10-30

Frequently asked questions

What is the current stock price of Intellia Therapeutics (NTLA)?

Intellia Therapeutics last traded at 10.00. This page shows a periodic quote snapshot. Check the displayed quote time.

What is Intellia Therapeutics's market cap?

About 1.40B.

What is the P/E ratio of Intellia Therapeutics?

The trailing twelve-month P/E is -2.99. The Valuation tab shows it against the stock's own five-year range.

Does Intellia Therapeutics pay a dividend?

Intellia Therapeutics does not currently pay a regular dividend.

Is Intellia Therapeutics a buy according to analysts?

The consensus of 11 analysts is a Hold rating, with an average 12-month price target of 19.20, which implies 92.0% upside from the current price. This is not investment advice.

What is Intellia Therapeutics's StockVane Quant Rating?

The StockVane Momentum strategy currently rates Intellia Therapeutics a D (Sell). Below its 200-day average or in the bottom third on momentum — the strategy is out of it. Not investment advice.

Quote time 2026-11-20 20:01:29 · For reference only, not investment advice and not tailored to your situation.

Intellia Therapeutics discussion 0 comments

Add a comment